insulin receptor

insulin receptor
Fletcher01 · CC BY-SA 3.0 · source
Name	Insulin receptor
Location	Chromosome 19
Discovered	1971
Type	Receptor tyrosine kinase

insulin receptor is a transmembrane receptor tyrosine kinase crucial for glucose homeostasis, metabolic regulation, and growth signaling. Characterized biochemically and genetically, it mediates responses to the peptide hormone insulin through conserved intracellular kinase domains and extracellular ligand-binding regions. Studies across models from Homo sapiens to Drosophila melanogaster and Mus musculus have elucidated its structure, activation, and roles in health and disease.

Structure and Isoforms

The receptor is synthesized as a single polypeptide encoded by the INSR gene on Chromosome 19 (human), undergoing proteolytic cleavage to form α and β subunits linked by disulfide bonds; key structural insights derive from cryo-electron microscopy efforts led by groups at University of Cambridge, Max Planck Institute, and Stanford University. Alternative splicing yields principal isoforms A and B with differing C-terminal sequences and affinities; evidence from laboratories at University of Oxford and Harvard Medical School shows isoform A predominance in fetal tissues and certain tumors, while isoform B predominates in differentiated tissues studied at Massachusetts Institute of Technology and University of California, San Francisco. The extracellular α-subunit contains ligand-binding L1, cysteine-rich, and L2 domains conserved with the insulin-like growth factor receptor characterized by researchers at Salk Institute and Cold Spring Harbor Laboratory. The β-subunit comprises a single-pass transmembrane helix and an intracellular tyrosine kinase domain homologous to kinases cataloged by European Bioinformatics Institute and National Institutes of Health protein databases.

Mechanism of Activation and Signaling Pathways

Insulin binding induces conformational changes and receptor autophosphorylation on specific tyrosine residues within the activation loop, a mechanism clarified by structural studies from Medical Research Council units and the Max Planck Society. Activated receptor recruits and phosphorylates adaptor proteins including insulin receptor substrate (IRS) family members characterized at University of Toronto and University of Cambridge, linking to downstream signaling cascades such as the phosphatidylinositol 3-kinase (PI3K)–AKT pathway described by teams at Cold Spring Harbor Laboratory and Sloan Kettering Institute, and the Ras–MAPK pathway investigated at Weizmann Institute of Science and Johns Hopkins University. Cross-talk with receptors for insulin-like growth factors studied at University of Pennsylvania and Imperial College London influences mitogenic and metabolic outputs; endocytic trafficking via clathrin-mediated pathways explored at European Molecular Biology Laboratory and Yale University modulates signaling duration, as do feedback loops involving suppressors like SOCS proteins identified by Karolinska Institute researchers.

Physiological Roles and Tissue Distribution

The receptor is widely expressed with high densities in liver, skeletal muscle, adipose tissue, brain, and endothelium, observations supported by expression atlases from Human Protein Atlas and atlases produced by Allen Institute for Brain Science. In hepatocytes studied at University of California, Los Angeles and University of Cambridge, it suppresses gluconeogenesis and promotes glycogen synthesis via AKT-mediated inhibition of GSK3, pathways originally mapped by teams at Rockefeller University and University of Chicago. In skeletal muscle and adipose tissue work from Karolinska Institute and University of Milan shows facilitation of glucose uptake through GLUT4 translocation, a process elucidated by laboratories at Institute Pasteur and University of California, San Diego. Central nervous system roles influencing appetite and cognition have been investigated at Columbia University and Princeton University, while vascular effects on nitric oxide production and endothelial function are topics of study at Imperial College London and Mount Sinai Health System.

Regulation and Post-translational Modifications

Regulation occurs at transcriptional, post-transcriptional, and post-translational levels; transcriptional control involves factors studied at National Institute of Diabetes and Digestive and Kidney Diseases and European Molecular Biology Laboratory. Glycosylation of the extracellular domain characterized by Max Planck Institute for Biochemistry affects folding and ligand binding, while ubiquitination by E3 ligases identified at University of Freiburg and Stanford University regulates receptor internalization and degradation. Phosphorylation at serine/threonine residues, mapped by proteomics groups at European Proteomics Association and Wellcome Trust Sanger Institute, modulates signaling strength and insulin sensitivity; negative regulation by protein tyrosine phosphatases such as PTP1B was demonstrated in studies at University of Chicago and Institut Pasteur. Endosomal sorting involving ESCRT machinery researched at University of Heidelberg contributes to receptor fate and resensitization dynamics.

Clinical Significance and Disease Associations

Mutations, splice variants, and dysregulation contribute to insulin resistance, type 2 diabetes mellitus, and rare severe insulin resistance syndromes described by clinical groups at Mayo Clinic and Cleveland Clinic. Overexpression or aberrant signaling associates with cancer biology in studies from National Cancer Institute and Dana-Farber Cancer Institute, particularly in breast, colon, and lung tumors analyzed at Johns Hopkins University Hospital and Memorial Sloan Kettering Cancer Center. Monogenic mutations causing leprechaunism and Rabson–Mendenhall syndrome were first characterized by investigators at Harvard Medical School and University of Chicago. Autoantibodies targeting the receptor documented in case series from University College London and Massachusetts General Hospital can produce hypoglycemia or insulin resistance. Genome-wide association studies involving consortia like DIAGRAM and GIANT link INSR pathway variation to metabolic phenotypes cataloged by European Bioinformatics Institute resources.

Pharmacology and Therapeutic Targeting

Therapeutic strategies include insulin analogs developed by companies and institutions such as Eli Lilly and Company, Novo Nordisk, and Sanofi to exploit receptor kinetics elucidated in collaborations with University of Toronto and Oxford University. Small-molecule modulators, monoclonal antibodies, and peptide mimetics targeting receptor activity have been investigated in translational research at Genentech and GlaxoSmithKline; dual targeting of IGF1 receptor and insulin receptor in oncology trials run by centers like Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center aims to limit tumor growth. Inhibitors of negative regulators, such as PTP1B antagonists researched at Baylor College of Medicine, and strategies to modulate receptor endocytosis examined at Karolinska Institutet represent alternative approaches. Clinical guidelines for diabetes management from American Diabetes Association and International Diabetes Federation reflect the centrality of receptor signaling in therapeutic decisions.

Category:Receptor tyrosine kinases